[go: up one dir, main page]

DE60332862D1 - 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen - Google Patents

17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen

Info

Publication number
DE60332862D1
DE60332862D1 DE60332862T DE60332862T DE60332862D1 DE 60332862 D1 DE60332862 D1 DE 60332862D1 DE 60332862 T DE60332862 T DE 60332862T DE 60332862 T DE60332862 T DE 60332862T DE 60332862 D1 DE60332862 D1 DE 60332862D1
Authority
DE
Germany
Prior art keywords
17beta
inhibitors
treatment
hydroxysteroid dehydrogenase
dehydrogenase type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332862T
Other languages
English (en)
Inventor
Kamil Paruch
Timothy J Guzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60332862D1 publication Critical patent/DE60332862D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60332862T 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen Expired - Lifetime DE60332862D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42726302P 2002-11-18 2002-11-18
PCT/US2003/036203 WO2004046111A1 (en) 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Publications (1)

Publication Number Publication Date
DE60332862D1 true DE60332862D1 (de) 2010-07-15

Family

ID=32326512

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332862T Expired - Lifetime DE60332862D1 (de) 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen

Country Status (16)

Country Link
US (2) US7074795B2 (de)
EP (1) EP1562901B1 (de)
JP (2) JP4614770B2 (de)
CN (1) CN100374421C (de)
AR (1) AR042046A1 (de)
AT (1) ATE469886T1 (de)
AU (1) AU2003290799A1 (de)
CA (1) CA2506290C (de)
CL (1) CL2003002356A1 (de)
DE (1) DE60332862D1 (de)
ES (1) ES2345146T3 (de)
MX (1) MXPA05005360A (de)
MY (1) MY130792A (de)
PE (1) PE20040750A1 (de)
TW (1) TW200412964A (de)
WO (1) WO2004046111A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060488A1 (en) 2002-12-17 2004-07-22 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
CA2606004A1 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US20140113887A1 (en) * 2011-04-25 2014-04-24 Jun-Hyoung Park Composition for topical application for preventing hair loss and stimulating hair growth
TW201512215A (zh) 2013-06-25 2015-04-01 Forendo Pharma Ltd 治療活性雌三烯噻唑衍生物
EP3013847B1 (de) 2013-06-25 2019-08-21 Forendo Pharma Ltd Therapeutisch aktive estratrienthiazolderivate als inhibitoren von 17.beta.-hydroxy-steroiddehydrogenase typ 1
AR096729A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados terapéuticamente activos de estratien-tiazol
WO2016102776A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd Prodrugs of 17.beta.-hsd1 -inhibitors
JP6545266B2 (ja) 2014-12-23 2019-07-17 フォレンド ファーマ リミテッド １７β‐ＨＳＤ１抑制剤のプロドラッグ
CN108137542B (zh) 2015-09-02 2023-10-27 葛兰素史克知识产权第二有限公司 用作溴结构域抑制剂的吡啶酮二甲酰胺
MX2022000747A (es) 2017-06-08 2023-01-24 Forendo Pharma Ltd Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas.
TWI810229B (zh) * 2017-12-15 2023-08-01 瑞士商英夕亞生物科技公司 側氧哌嗪衍生物
BR112021010598A2 (pt) 2018-12-05 2021-08-24 Forendo Pharma Ltd Compostos, método para preparação de um composto e composição farmacêutica

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680016B2 (ja) 1984-08-02 1994-10-12 ラブリ−，フエルナンド ホルモン依存性がんの併用治療のための医薬組成物
IE62715B1 (en) 1989-03-10 1995-02-22 Endorecherche Inc Combination therapy for treatment of estrogen sensitive diseases
AU5851690A (en) 1989-07-07 1991-02-06 Endorecherche Inc. Method of treatment of androgen-related diseases
WO1991000731A1 (en) 1989-07-07 1991-01-24 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
CZ285893B6 (cs) 1993-05-17 1999-11-17 Endorecherche Inc. Antiandrogenní sloučenina, její prekursor a farmaceutický prostředek ji obsahující
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
IL128931A0 (en) * 1996-09-13 2000-02-17 Schering Corp Tricylic antitumor compounds being farnesyl protein transferase inhibitors
BR9908592A (pt) 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
US6903102B2 (en) 2001-09-06 2005-06-07 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
JP4309761B2 (ja) * 2001-10-17 2009-08-05 シェーリング コーポレイション アンドロゲン依存性疾患の治療を目的とする１７βヒドロキシステロイドデヒドロゲナーゼ３型の阻害剤としてのピペリジンアセトアミンおよびピペラジンアセトアミン

Also Published As

Publication number Publication date
ATE469886T1 (de) 2010-06-15
US20060148816A1 (en) 2006-07-06
US7074795B2 (en) 2006-07-11
MXPA05005360A (es) 2005-08-03
TW200412964A (en) 2004-08-01
EP1562901B1 (de) 2010-06-02
EP1562901A1 (de) 2005-08-17
US20040127503A1 (en) 2004-07-01
CN100374421C (zh) 2008-03-12
ES2345146T3 (es) 2010-09-16
PE20040750A1 (es) 2004-11-06
CA2506290A1 (en) 2004-06-03
JP2010138204A (ja) 2010-06-24
CA2506290C (en) 2012-04-24
US7476681B2 (en) 2009-01-13
JP4614770B2 (ja) 2011-01-19
JP2006513169A (ja) 2006-04-20
CL2003002356A1 (es) 2005-02-11
WO2004046111A1 (en) 2004-06-03
MY130792A (en) 2007-07-31
CN1738800A (zh) 2006-02-22
AU2003290799A1 (en) 2004-06-15
AR042046A1 (es) 2005-06-08
HK1073313A1 (en) 2005-09-30

Similar Documents

Publication Publication Date Title
DE60217363D1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen
EP1482962A4 (de) Verfahren zur behandlung von trx-vermittelten erkrankungen
DE60332862D1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
ATE414699T1 (de) Inhibitoren von tyrosinkinasen
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
ATE556059T1 (de) Pyrazolderivate zur behandlung von hiv
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
EP2054058A4 (de) Pyruvatkinasehemmer und verfahren zur behandlung von erkrankungen
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
EP1556085A4 (de) Verbindungen zur behandlung von stoffwechselst rungen
EP1651237A4 (de) Verfahren zur behandlung von dermatologischen erkrankungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
EP1309552A4 (de) Verbindungen und hemmer von phospholipasen
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen